Cyclophosphamide drug makes the bone marrow more tumor-friendly - News-Medical.Net

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily. The findings provide valuable insight as to ...

Poor-prognosis Estrogen Receptor-positive Disease : Combining Anti-her-2 and Endocrine Therapy - Medscape News

Anthra, anthracycline; cont, containing; DD, dose dense; doce, docetaxel; ER−, estrogen receptor negative; ER+, estrogen receptor positive; FAC, fluorouracil (5-FU), doxorubicin and cyclophosphamide regimen; FEC, 5-FU, epirubicin and cyclophosphamide ...

How Chemotherapy Boosts Bone Cancer Growth - Softpedia

McCauley, the principal investigator on the new study, reveals that the chemotherapy drug called cyclophosphamide is responsible for the ill side effect. On the bright side of things, she believes that a solution to this problem may have already been found.

Commonly Used Chemo Drug Could Aid the Spread of Cancer Cells into Bones by Fertilizing Bone Marrow - Med India

The really good news is that researchers reversed the tumor-friendly effect of the drug, called cyclophosphamide, by inhibiting another cell-communicating protein in the bone marrow, called CCL2. "This work is early and still at the pre-clinical ...

'Fertilizing' bone marrow helps answer why some cancers spread to bones - sciencecodex.com

The really good news is that researchers reversed the tumor-friendly effect of the drug, called cyclophosphamide, by inhibiting another cell-communicating protein in the bone marrow, called CCL2. "This work is early and still at the pre-clinical ...

Poor-prognosis Estrogen Receptor-positive Disease - Medscape News

Anthra, anthracycline; cont, containing; DD, dose dense; doce, docetaxel; ER−, estrogen receptor negative; ER+, estrogen receptor positive; FAC, fluorouracil (5-FU), doxorubicin and cyclophosphamide regimen; FEC, 5-FU, epirubicin and ...

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides - Elites TV

CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1 ...

Some doctors unaware of long-term side effects of cancer care - CNN

In the case of Cyclophosphamide, only 14% of primary care physicians knew women are likely to suffer premature menopause, compared to 71% of cancer specialists. Study author Dr. Larissa Nekhlyudov says these physicians need to be informed about ...

Majority Of Doctors Don't Know About Long-Term Chemotherapy Risks: Study - Huffington Post

The doctors were asked which of five side effects they had observed most often in their practices or seen reported for each of four widely used chemotherapy drugs: doxorubicin, paclitaxel, oxaliplatin and cyclophosphamide. The researchers found ...